事件：公司发布2025 年三季报。 2025 年前三季度，公司实现营业收入49.76 亿元，同比增长1.27%；实现归母净利润5.84 亿元，同比增 长12.65%；实现扣非归母净利润4.31 亿元，同比增长1.61%。单季度来看，2025Q3 公司实现营业收入 16.17 亿元，同比增长10.42%；实现归母净利润2.30 亿元，同比增长69.11%；实现扣非归母净利润1.35 亿元，同比增长53.21%。同时，公司积极加强资金集中管理与各大事业部的精益化管理，前三季度经 营现金流净额同比增长16%，存货周转率同比提升，经营质量稳步向好。 2025Q1-3 全品类中药及特色健康消费品板块实现增长。 公司坚持以全品类中药产品为主体，以特色化学药品、特色健康消费品为两翼的战略定位，2025Q1-3 公司全品类中药业务实现收入26.76亿元，同比增长5.73%；特色化学药业务实现收入17.20 亿元，同比 下降7.16%，主要系部分化药品种受集采未中选或集采降价影响同比略下降；特色健康消费品业务实现 收入4.85 亿元，同比增长12.41%。 2025Q1-3 公司部分重点品种增长突出，其中肠炎宁系列通过联动屁桃 ...

2025Q1-3 业绩稳健，十五五规划积极 制定中 事件：公司发布 2025 年三季报。 2025 年前三季度，公司实现营业收入 49.76 亿元，同比增长 1.27%； 实现归母净利润 5.84 亿元，同比增长 12.65%；实现扣非归母净利润 4.31 亿元，同比增长 1.61%。单季度来看，2025Q3 公司实现营业收 入 16.17 亿元，同比增长 10.42%；实现归母净利润 2.30 亿元，同比 增长 69.11%；实现扣非归母净利润 1.35 亿元，同比增长 53.21%。同 时，公司积极加强资金集中管理与各大事业部的精益化管理，前三季 度经营现金流净额同比增长 16%，存货周转率同比提升，经营质量稳 步向好。 2025Q1-3 全品类中药及特色健康消费品板块实现增长。 公司坚持以全品类中药产品为主体，以特色化学药品、特色健康消费 品为两翼的战略定位，2025Q1-3 公司全品类中药业务实现收入 26.76 亿元，同比增长 5.73%；特色化学药业务实现收入 17.20 亿元，同比 下降 7.16%，主要系部分化药品种受集采未中选或集采降价影响同比 略下降；特色健康消费品业务实现收入 4.85 ...

资金流向方面，主力资金净流出5192.81万元，特大单买入1599.14万元，占比5.81%，卖出4133.29万 元，占比15.02%；大单买入5679.15万元，占比20.63%，卖出8337.82万元，占比30.29%。 康恩贝今年以来股价涨3.23%，近5个交易日涨4.25%，近20日涨6.88%，近60日涨0.22%。 10月31日，康恩贝盘中上涨2.19%，截至14:07，报4.66元/股，成交2.75亿元，换手率2.37%，总市值 117.66亿元。 分红方面，康恩贝A股上市后累计派现37.27亿元。近三年，累计派现12.67亿元。 机构持仓方面，截止2025年9月30日，康恩贝十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股5073.91万股，相比上期增加2396.39万股。南方中证1000ETF（512100）位居第八大流通股 东，持股1652.47万股，相比上期减少17.61万股。汇添富中证中药ETF（560080）位居第十大流通股 东，持股1128.85万股，为新进股东。景顺长城中证红利低波动100ETF（515100）退出十大流通股东之 列。 责任编辑：小浪快报 资料显示 ...

一场关于蛋白粉的"标准革命"，正在悄然发生。 你选择的蛋白粉，是否真的符合高效、安全、透明的现代营养标准？ 长期以来，蛋白粉市场存在蛋白质含量差异大、品质不一、标签不规范等问题，严重影响消费者体验与行业健康发展。 近期康恩贝（600572）联合江南大学、中国农业大学等五所高校，共同推动制定并发布了全国首个《蛋白粉》团体标准（T/ACCEM 596—2025）。该标 准明确要求蛋白质含量须达80%以上，并对原料来源、污染物限量、标识标注等关键指标作出统一要求，为行业树立清晰的质量门槛。 不止于立标，更实现技术突破 康恩贝金冠 蛋白粉，其蛋白质含量实测达94.6g/100g，约为牛奶的31.5倍，获"90%蛋白粉开创者"认证。 作为国有控股大型医药健康企业，依托其药企背景，康恩贝将药品级质量管理体系延伸至营养品制造，从原料筛选到工艺控制均执行严格标准。 "科研创新+标准建设"双轮驱动 作为浙江省健康产业领军企业，康恩贝深耕大健康领域已逾50年。此次获得行业双标杆认证，不仅印证了企业的创新能力，更承载着推动行业升级的使 命。 聚焦技术研发与品质提升，为全民健康提供更专业、更高效的营养支持。 那么，你喝的蛋白粉，到底 ...

Core Insights - Hangzhou Kang En Bei Pharmaceutical's application for the generic version of Finerenone has been accepted, with 30 companies currently competing for the first generic approval [1][7][10] - Finerenone, originally developed by Bayer, is used for treating type 2 diabetes-related chronic kidney disease (CKD) and heart failure, showing strong market performance with sales exceeding 410 million yuan in the first half of 2025, a 135.98% year-on-year increase [4][10] - The original patent for Finerenone is set to expire in February 2028, with 23 companies currently filing for a type 3 patent declaration, indicating they cannot market the product until the patent expires [10][13] Company Developments - Kang En Bei Pharmaceutical has successfully obtained approvals for over 50 products, with several being the first to pass consistency evaluations, including Sulfamethoxazole and Amisulpride solutions [16] - The competition for Finerenone has intensified, with 37 companies having completed bioequivalence (BE) trials and over 20 more currently conducting BE trials [13][16] Market Dynamics - The strong sales performance of Finerenone has attracted numerous domestic pharmaceutical companies to enter the market, leading to a competitive landscape [4][7] - The ongoing patent challenges and the competitive nature of the generic drug market suggest a dynamic environment for both original and generic manufacturers [10][13]

Core Insights - The internet healthcare sector experienced a slight increase of 0.21% on October 29, with notable gains from companies like Jiangyu Pingmin, which rose by 6.29% [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Company Performance - Jiangyu Pingmin (301017) closed at 11.99 with a gain of 6.29%, trading volume of 201,100 shares and a transaction value of 242 million [1] - Furuishi (300049) closed at 74.48, up 6.20%, with a trading volume of 150,500 shares and a transaction value of 1.104 billion [1] - Xingqi Eye Medicine (300573) closed at 82.01, increasing by 5.29%, with a trading volume of 309,400 shares and a transaction value of 2.518 billion [1] - Other notable performers include Maidi Technology (603990) with a 2.98% increase and a transaction value of 384 million, and Hanhui Technology (300007) with a 2.68% increase and a transaction value of 1.402 billion [1] Market Dynamics - The internet healthcare sector saw a net outflow of 1.125 billion from institutional investors, while retail investors contributed a net inflow of 926 million [2][3] - The overall market sentiment indicated a mixed response, with some stocks experiencing significant declines, such as Jiayuan Technology (301117) which fell by 13.29% [2] - The trading activity highlighted a divergence in investor behavior, with institutional investors pulling back while retail investors remained active [2][3]

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 301315 | 威士顿 | 19.99 | 47.99 | 51.44 | 61.52 | 19.60 | | 301333 | 诺思格 | 20.00 | 15.54 | 51.85 | 61.92 | 19.43 | | 000034 | 神州数 码 | 7.88 | 13.55 | 40.39 | 43.54 | 7.79 | | 002391 | 长青股 份 | 9.97 | 10.62 | 6.04 | 6.51 | 7.77 | | 688223 | 晶科能 源 | 7.01 | 1.78 | 5.43 | 5.80 | 6.82 | | 000007 | 全新好 | 7.57 | 4.70 | 7.46 | 7.96 | 6.76 | | 920670 | 数字人 | 15.20 | 16.90 | 15.36 | 16.37 | ...

Core Insights - 康恩贝 reported a total operating revenue of 4.976 billion yuan for Q3 2025, ranking 7th among disclosed peers, with a year-on-year increase of 62.573 million yuan, representing a 1.27% growth compared to the same period last year [1] - The net profit attributable to shareholders reached 584 million yuan, ranking 9th among peers, with an increase of 65.577 million yuan, reflecting a year-on-year growth of 12.65% [1] - The net cash inflow from operating activities was 532 million yuan, ranking 9th among peers, with an increase of 73.0795 million yuan, showing a year-on-year growth of 15.94% [1] Financial Ratios - The latest debt-to-asset ratio is 29.33%, a decrease of 0.21 percentage points from the previous quarter and a decrease of 1.39 percentage points from the same period last year [3] - The latest gross profit margin is 53.78%, an increase of 0.06 percentage points from the previous quarter and an increase of 0.05 percentage points from the same period last year [3] - The latest return on equity (ROE) is 8.27%, ranking 13th among peers, with an increase of 0.48 percentage points from the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is 0.23 yuan, ranking 17th among peers, with an increase of 0.03 yuan, representing a year-on-year growth of 13.17% [3] - The latest total asset turnover ratio is 0.50 times, ranking 6th among peers, with an increase of 0.03 times from the same period last year, reflecting a year-on-year growth of 6.09% [3] - The latest inventory turnover ratio is 1.91 times, ranking 13th among peers, with an increase of 0.19 times, achieving five consecutive years of growth, and a year-on-year increase of 11.10% [3] Shareholder Structure - The number of shareholders is 86,700, with the top ten shareholders holding 1.139 billion shares, accounting for 45.12% of the total share capital [3] - The largest shareholder is 浙江省医药健康产业集团有限公司, holding 23.53% of the shares [3]

（编辑 楚丽君） 证券日报网讯 10月28日晚间，康恩贝发布公告称，2025年10月27日，浙江康恩贝制药股份有限公司 （以下简称"公司"）全资子公司杭州康恩贝制药有限公司（以下简称"杭州康恩贝"）参加了国家组织第 十一批药品集中带量采购工作。经国家组织药品联合采购办公室（以下简称"联合采购办公室"）开标、 评标，杭州康恩贝的产品腺苷钴胺胶囊拟中标本次集中采购。腺苷钴胺胶囊已经根据各省市场潜力进行 了供应省份遴选，中选结果将在联合采购办公室公示后正式发布。 ...

Core Insights - The company reported a total operating revenue of 1,617,233,491.76 yuan for the third quarter of 2025, representing a year-on-year increase of 10.42% [1] - The net profit attributable to shareholders of the listed company was 230,426,927.77 yuan, showing a significant year-on-year growth of 69.11% [1] Financial Performance - Operating revenue for Q3 2025: 1,617,233,491.76 yuan, up 10.42% year-on-year [1] - Net profit for Q3 2025: 230,426,927.77 yuan, up 69.11% year-on-year [1]